$3,406.38 general Payment -- AbbVie Inc to Dr. Melissa Reed

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

This payment of $3406.38 from AbbVie Inc. to Dr. Melissa Reed, an Oncologist in Greensboro, NC, was for general compensation for services other than consulting. This means Dr. Reed likely provided expertise or performed services for AbbVie that weren't specifically advisory in nature. The payment is associated with Eylea, a drug manufactured by Regeneron Pharmaceuticals, but AbbVie is listed as the payer. This could indicate a variety of arrangements, such as speaker fees for educational events, participation in advisory boards (though the payment type is 'general'), or other professional services. The amount itself, while significant, is not extraordinarily high for an oncologist who may engage in various professional activities with pharmaceutical companies. Oncologists often work with drug manufacturers to stay abreast of new treatments and share their clinical experience. Potential conflict of interest considerations arise because payments from drug companies could, consciously or unconsciously, influence a physician's prescribing habits towards the company's products. However, it's crucial to remember that such payments are legal and regulated under the Sunshine Act, and the payment itself does not prove any wrongdoing or biased decision-making. This payment is within a range that might be considered typical for an oncologist involved in industry-related activities. Many physicians in specialized fields like oncology receive payments for their expertise. Patients should understand that these relationships are common and are designed to facilitate the exchange of medical knowledge. Transparency through the Open Payments database allows patients to be informed about these financial ties.

Patient Guidance: What This Payment Means for You

It's understandable to feel curious or concerned when you see payments between pharmaceutical companies and your doctor. This payment of $3406.38 from AbbVie to Dr. Reed is for general services, not consulting. This means she likely provided some form of professional service or expertise. While this payment doesn't automatically mean your care will be affected, it's always wise to maintain open communication. At your next appointment, you can ask Dr. Reed directly about her professional relationships with pharmaceutical companies. You might say, 'I saw on the Open Payments database that AbbVie made a payment to you. Could you tell me more about the nature of that relationship and how it helps you stay current with treatments?' This payment is for a specific service and isn't an ongoing retainer, which can be reassuring. However, if your doctor prescribes a medication and you have questions about why that specific drug was chosen over others, or if you feel pressured into a particular treatment, that's when you should voice your concerns more strongly. Routine payments for services are common, but any payment that makes you question your doctor's objectivity warrants a direct conversation.

Payment Context: Is This Amount Normal?

Oncologists often receive payments from pharmaceutical companies for various services, including speaking engagements, advisory roles, and research. Payments can range from a few hundred to several thousand dollars per engagement. A significant percentage of oncologists receive payments, reflecting the close relationship between the specialty and drug development. This $3406.38 payment falls within a typical range for professional services rendered by an oncologist.

Regulatory Context: Sunshine Act Requirements

The Sunshine Act, part of the Affordable Care Act, requires pharmaceutical and medical device companies to report payments and other transfers of value made to physicians and teaching hospitals. This payment of $3406.38 would be subject to reporting if it met the minimum threshold, which is generally $10 or more. AbbVie is required to report this transaction to CMS, which then makes it publicly available through the Open Payments database. This type of general compensation payment is a standard category of reportable transactions.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharma-payments
• oncology
• sunshine-act
• physician-compensation
• abbvie
• eylea
• conflict-of-interest

Understanding general Payments

general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.

Frequently Asked Questions About This Payment

Does my doctor take pharma money?

You can find out by searching the CMS Open Payments database online. This database lists payments made by pharmaceutical and medical device companies to physicians and teaching hospitals. If your doctor's name appears, it means they have received payments. These payments can be for various reasons, such as speaking at educational events, consulting, research, or providing other professional services. Seeing a payment doesn't automatically mean your doctor is biased, but it does provide transparency about their financial relationships with the industry. It's a tool to help you have informed conversations with your healthcare provider.

Should I worry about this payment?

This specific payment of $3406.38 from AbbVie to Dr. Reed is for general services. While any payment from a drug company to a doctor can raise questions about potential influence, this amount and type of payment are not inherently alarming. Many oncologists engage with pharmaceutical companies to stay informed about new treatments. The key is transparency and communication. If you have concerns about your treatment plan or feel your doctor's recommendations might be influenced, it's best to discuss it directly with them. This payment alone doesn't indicate a problem, but it's a good reason to be an engaged patient.

What types of pharma payments are most concerning?

Payments that raise the most concern are often those that are less transparent or seem directly tied to prescribing specific drugs without clear justification. This includes large, recurring payments for 'consulting' or 'advisory' roles that lack a defined scope of work, or payments for speaking engagements that appear to be thinly veiled marketing. Payments for speaker programs, speaker bureaus, and significant consulting fees can be more concerning than payments for legitimate research or educational activities. However, even these are legal and regulated; the concern lies in the potential for undue influence on prescribing decisions.

How do I talk to my doctor about pharma relationships?

Start by acknowledging the transparency provided by the Open Payments database. You could say, 'I saw on the Open Payments website that [Pharma Company] made a payment to you. Could you help me understand what that was for?' or 'I'm interested in understanding how you stay up-to-date on new medications. Do you work with pharmaceutical companies in any capacity?' Frame your questions around your care and understanding. Ask about the rationale behind your treatment plan, especially if multiple drug options exist. For example, 'Why is this particular medication the best choice for me?' This approach fosters an open dialogue rather than an accusatory one.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for doctors to accept payments from pharmaceutical and medical device companies, provided these payments are properly reported under the Sunshine Act. The Sunshine Act requires companies to disclose payments made to physicians and teaching hospitals, creating a public database (CMS Open Payments). These payments can be for a variety of legitimate reasons, such as consulting, speaking at educational events, research, or providing other professional services. The law aims to increase transparency, allowing patients to see these financial relationships. The key is that these payments must be disclosed and are subject to regulations.

Does pharma money affect what my doctor prescribes?

Research suggests that financial relationships between doctors and pharmaceutical companies can influence prescribing patterns. Doctors who receive payments may be more likely to prescribe the products of the companies that pay them. This influence can be subtle and may not always be conscious. However, it's important to note that many physicians maintain their professional judgment, and payments are often for legitimate services like education or research. The Sunshine Act aims to mitigate potential bias by making these relationships public, allowing patients to be informed and ask questions about their treatment choices.

How does this compare to other doctors in this specialty?

Oncology is a field where physicians frequently interact with pharmaceutical companies due to the nature of cancer drug development and treatment. Therefore, it's common for oncologists to receive payments for their expertise, whether for speaking, consulting, or participating in research. The average number of payments and the total amount received by oncologists can be higher than in some other specialties. This specific payment of $3406.38 is a single transaction and, while substantial, is not necessarily out of line with what an oncologist might receive for providing professional services to a drug manufacturer.

Related Reports

• View Dr. Melissa Reed's full payment report
• AbbVie Inc full spending report
• Browse all Oncology payments
• Browse all payments in North Carolina
• Search for other payments